Navigation Links
Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
Date:9/4/2007

- ViziLite Plus with TBlue630 -

PHOENIX, Sept. 4 /PRNewswire-FirstCall/ -- Zila, Inc.'s (Nasdaq: ZILA) ViziLite(R) Plus with Tblue630(TM) screening system for early detection of abnormalities which can lead to oral cancer, has been selected to identify pre-cancerous lesions in a Phase II study of Cetuximab (ERBITUX(R)), a leading cancer therapeutic for head and neck cancer developed by ImClone Systems (Nasdaq: IMCL) and distributed by Bristol-Meyers Squibb (NYSE: BMY).

The NIH has awarded a Specialized Program of Research Excellence (SPORE) grant for the study. The primary objective of the clinical trial is to evaluate ERBITUX efficacy in treating upper aerodigestive pre-cancer. ERBITUX is currently marketed for the treatment of head and neck cancer (including upper aerodigestive) as well as metastatic colorectal cancer.

Dr. Frank J.Bellizzi, President of Zila Pharmaceuticals, "We are pleased that Zila's ViziLite Plus with Tblue630 has been selected for use in this clinical trial. The use of ViziLite Plus in such an important study with the leading head and neck cancer therapeutic demonstrates its growing reputation as the premier oral cancer screening technology."

The coordinating center for the study is The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. The Protocol Chairman is Joseph Califano, M.D., of the Department of Otolaryngology-Head and Neck Surgery.

Over 30 clinical investigators at key academic research institutions and cancer research centers are scheduled to participate in the study. The Phase II study is anticipated to enroll and evaluate approximately 60 patients over a three-year period. Patients will be evaluated clinically and biopsies will be taken pre- and post-treatment. The biopsies will be analyzed histopathologically, but will also be analyzed for genetic changes using Zila's proprietary LOH assay. The assay is the only validated method for identifying biomarkers consistent with oral premalignencies and oral cancer.

About ViziLite(R) Plus

ViziLite(R) Plus is an oral screening technology that utilizes ViziLite, an advanced chemiluminescent light technology, with Tblue630. The Tblue630 marking system employs Zila Tolonium Chloride (ZTC(TM)), the only patented pharmaceutical-grade form of toluidine blue in an FDA-cleared device.

For more information about ViziLite Plus, visit http://www.vizilite.com.

About Zila's LOH Assay

Biopsies are traditionally analyzed histopathologically to determine the histological changes in diseased tissue and enable classification of the tissue such as benign, dysplastic or cancerous. Leading cancer centers now recognize the value of also evaluating the DNA of biopsy samples for markers that signal that tissue is on the progression pathway to cancer. Zila has developed a proprietary DNA assay that evaluates chromosomal deletions by determining the loss of heterozygosity (LOH) of such biopsies. The validated LOH assay is utilized in the Zila OraTest Phase III clinical trial as well as the Erbitux Study, and the Company is evaluating commercial opportunities for the test.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is an oral cancer screening company focused on the prevention and treatment of oral disease. Zila is dedicated to establishing ViziLite(R) Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer, with an initial focus on the dental market through Pro-Dentec(R), a leading designer, manufacturer and marketer of Soft Tissue Management (STM(R)) products. Sold exclusively and directly to dental professionals, Pro-Dentec's core products include the Rota-dent(R) Professional Powered Brush, the Pro-Select3(R) Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM(R) products for both in-office and home-care use.

For more information about Zila, visit http://www.zila.com.


'/>"/>
SOURCE Zila, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
5. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. PromegaExpress Expands Easy Access to Products with New Cabinet
9. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
10. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
11. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
Breaking Medicine News(10 mins):